Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.

NCT00559871 is registered in ClinicalTrials.gov with Juvantia Pharma Ltd as lead sponsor.

NCT NCT00559871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00559871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.
Lead sponsor
Juvantia Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
May 31, 2009
Enrollment
180 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease